基于网络的互动式决策项目对多发性硬化复发管理的影响:POWER@MS2随机对照试验方案
多发性硬化急性复发常用大剂量糖皮质激素静脉治疗,但口服不劣于静脉且长期获益未证实。本研究为实用性双盲随机对照试验,纳入188例近一年至少1次或近两年至少2次复发的患者,评估基于网络和对话的决策辅助项目能否改变复发管理并增强自主性,主要终点为未治疗或口服激素治疗的复发比例。
要点
- 干预组接受网络决策辅助、护士网络研讨会和监控聊天论坛。
- 主要终点为未治疗或口服激素治疗的复发比例。
- 研究采用意向性治疗分析,随访至记录81次复发或每例观察24个月。
核心结论
- 研究假设干预将增强患者赋权并对复发管理产生积极影响。
研究设计与样本
- 实用性双盲随机对照试验,遵循英国医学研究理事会复杂干预开发与评估指南。
- 计划招募188例可能或复发缓解型多发性硬化患者,近一年至少1次复发和/或近两年至少2次复发。
- 采用区组随机化,干预组接受网络决策辅助、护士网络研讨会和监控聊天论坛,对照组接受通过同一在线平台提供的标准信息。
- 伴随混合方法过程评估和卫生经济学评估。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要终点为未治疗或口服糖皮质激素治疗的复发比例。
- 关键次要终点包括年化复发率、决策、赋权、生活质量和成本效果。
- 研究在记录81次复发或每例患者观察24个月后结束。
- 分析遵循意向性治疗原则。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Multiple sclerosis is a chronic inflammatory, degenerative disease of the central nervous system manifesting at first with relapses in about 85% of cases. In Germany, intravenous therapy with high-dose corticosteroids is the treatment standard of acute relapses. The treatment leads to a faster reduction of symptoms in about 25 of 100 treated patients but has no proven long-term benefits over placebo treatment. Intravenous treatment is not superior to oral treatment. Therefore, informed decisions on relapse management are required. An earlier randomised controlled trial showed that evidence-based patient information and education on relapse management leads to more informed decisions and more relapses not treated or treated with oral corticosteroids. This study aims to evaluate whether a web-based relapse management programme will positively change relapse management and strengthen autonomy in people with multiple sclerosis. METHODS: The pragmatic double-blind randomised controlled trial is accompanied by a mixed-methods process evaluation and a health economic evaluation and follows the UK Medical Research Council guidance on developing and evaluating complex interventions. A total of 188 people with possible or relapsing-remitting multiple sclerosis with ≥ 1 relapse within the last year and/or ≥ 2 relapses within the last 2 years will be recruited and randomised using blocks. The intervention group receives a web- and dialogue-based decision aid on relapse management, a nurse-led webinar and access to a monitored chat forum. The control group receives standard information, which will be made available via the same online platform as the intervention. The primary endpoint is the proportion of relapses not treated or treated with oral corticosteroids. Key secondary endpoints are the annualised relapse rate, decision-making, empowerment, quality of life and cost-effectiveness. Facilitators and barriers will be assessed by mixed-methods process evaluation measures. The study ends when 81 relapses have been documented or after 24 months of observation per individual patient. Analyses will follow the intention-to-treat principle. DISCUSSION: We hypothesise that the intervention will enhance patient empowerment and have a positive impact on patients' relapse management. TRIAL REGISTRATION: ClinicalTrials.gov NCT04233970 . Registered on 18 January 2020.
引用
- Rahn AC, Wenzel L, Icks A, et al. Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)-study protocol for a randomised controlled trial. Trials. 2021. PMID: 33583424. doi:10.1186/s13063-021-05059-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。